Literature DB >> 16086642

Controlling sialorrhoea: a review of available treatment options.

Anna Potulska1, Andrzej Friedman.   

Abstract

Sialorrhoea (drooling or excessive salivation) is a common symptom of many neurological diseases (e.g., amyotropic lateral sclerosis, cerebral palsy and Parkinson's disease) and otolaryngologic diseases (tumours of upper aerodigestive tract). It is mostly caused by poor oral and facial muscle control in patients with swallowing dysfunction (secondary sialorrhoea). However, some cases of sialorrhoea are due to hypersecretion of saliva. These cases represent so-called primary sialorrhoea.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086642     DOI: 10.1517/14656566.6.9.1551

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  Impact of drooling in Parkinson's disease.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Marten Munneke
Journal:  J Neurol       Date:  2007-08-02       Impact factor: 4.849

Review 2.  World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment.

Authors:  Alessandro Villa; Andy Wolff; Doron Aframian; Arjan Vissink; Jörgen Ekström; Gordon Proctor; Richard McGowan; Nagamani Narayana; Ardita Aliko; Ying Wai Sia; Revan Kumar Joshi; Siri Beier Jensen; Alexander Ross Kerr; Colin Dawes; Anne Marie Lynge Pedersen
Journal:  Clin Oral Investig       Date:  2015-05-22       Impact factor: 3.573

3.  Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.

Authors:  João Costa; Maria Luz Rocha; Joaquim Ferreira; Teresinha Evangelista; Miguel Coelho; Mamede de Carvalho
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

Review 4.  Medication-Induced Xerostomia and Hyposalivation in the Elderly: Culprits, Complications, and Management.

Authors:  Anna Greta Barbe
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

5.  Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions.

Authors:  Koji Makino; Neil Mahant; Dominic Tilden; Lara Aghajanian
Journal:  Neurol Ther       Date:  2020-03-12

6.  Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.

Authors:  Stuart H Isaacson; William Ondo; Carlayne E Jackson; Richard M Trosch; Eric Molho; Fernando Pagan; Mark Lew; Khashayar Dashtipour; Thomas Clinch; Alberto J Espay
Journal:  JAMA Neurol       Date:  2020-04-01       Impact factor: 18.302

7.  Radiation of parotid or submandibular glands is effective for drooling in patients with parkinsonism; a randomised double-blind placebo-controlled trial.

Authors:  R J H M Steenbakkers; S P van Doornik; A Vissink; W Kerdijk; T van Laar
Journal:  Clin Park Relat Disord       Date:  2022-02-14

8.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

9.  Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated.

Authors:  Domenico A Restivo; Mariangela Panebianco; Antonino Casabona; Sara Lanza; Rosario Marchese-Ragona; Francesco Patti; Stefano Masiero; Antonio Biondi; Angelo Quartarone
Journal:  Toxins (Basel)       Date:  2018-01-27       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.